Margreet G.E.M. Ausems

Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families

Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium

Patients’ experiences with pre-test genetic counseling provided by breast cancer healthcare professionals: Results from a large prospective multicenter study

Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study

Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer

Systematic development of a training program for healthcare professionals to improve communication about breast cancer genetic counseling with low health literate patients

Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

‘We don’t know for sure’: discussion of uncertainty concerning multigene panel testing during initial cancer genetic consultations

Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i>/<i>2</i> Mutation Carriers: A Mendelian Randomization Study

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD

Serum AMH levels in healthy women from<i>BRCA1/2</i>mutated families: are they reduced?

Am I My Family's Keeper? Disclosure Dilemmas in Next-Generation Sequencing

Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers

Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk

Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)

BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers